Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Glioblastoma (GBM) is a heterogeneous cancer with variable clinical outcomes.
• Isocitrate dehydrogenase (IDH)-wildtype GBM presents a particular challenge for prognosis due to its complexity.
• Distinguishing between IDH-wildtype GBM subtypes is crucial for effective treatment planning.

Purpose of the Study:

• To identify novel gene expression biomarkers for IDH-wildtype glioblastoma.
• To develop a robust prognostic signature for predicting patient survival.
• To refine the classification of IDH-wildtype GBM for personalized therapeutic approaches.

Main Methods:

• Utilized RNA sequencing data from Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) cohorts.
• Applied univariate Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression to identify candidate genes and formulate a risk signature.
• Validated the seven-gene signature using Kaplan-Meier analysis, log-rank tests, and Cox regression in independent patient cohorts.
• Performed Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) for functional characterization.

Main Results:

• A seven-gene-based risk signature was developed, effectively stratifying patients into low- and high-risk groups.
• The high-risk group exhibited significantly shorter overall survival compared to the low-risk group across multiple cohorts.
• The seven-gene signature demonstrated superior prognostic validity (AUC 78.4% and 73.9%) compared to age and GBM sub-type.
• Bioinformatics analysis indicated the signature's involvement in inflammatory response, immune response, cell adhesion, and apoptosis.

Conclusions:

• The developed seven-gene signature serves as a potential prognostic biomarker for IDH-wildtype glioblastoma.
• This signature refines the current classification of IDH-wildtype GBM, offering improved prognostic accuracy.
• The findings provide a novel perspective for research and the development of individualized therapies for IDH-wildtype GBM.